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Abstract This study investigates potential associations between CD36 gene
variants and the presence of risk factors in Caucasians with coronary artery disease
(CAD) manifested at a young age. The study group consisted of 90 patients; the men
were B 50 years old and the women were B 55 years old. Amplicons of exons 4
and 5 including fragments of introns were analyzed by DHPLC. Two polymor-
phisms were found: IVS3-6 T/C (rs3173798) and IVS4-10 G/A (rs3211892). The C
allele of the IVS3-6 T/C polymorphism was associated with higher prevalence of
obesity and diabetes, higher hsCRP, lower Lp(a) serum concentrations, and younger
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DOI 10.1007/s10528-011-9475-zage at myocardial infarction. The A allele of the IVS4-10 G/A polymorphism was
associated with older age of myocardial infarction and higher white blood cell
count. The functional role of CD36 polymorphisms in CAD development needs
further research.
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Introduction
CD36 is a type B scavenger receptor located on the surface of many cell types:
platelets, endothelial cells, macrophages, dendrite cells, adipocytes, striated muscle
cells, and hematopoietic cells (Greenwalt et al. 1992; Nicholson et al. 2001). The
functions of CD36 include removal of oxidized LDL (oxLDL) and fatty acid from
plasma by macrophages and monocytes (Park et al. 2009; Rac ´ et al. 2007), induction
of apoptosis (Silverstein 2009), and enhancement of cytoadherence of abnormally
shaped erythrocytes (Chilongola et al. 2009).
CD36 may play an important role in the pathogenesis of some metabolic
diseases. There are reports pointing to increased total and LDL cholesterol serum
levels in association with mutations of the CD36 gene (Yanai et al. 2000). CD36 has
been reported to play an important role in atherogenicity (Huszar et al. 2000). There
have been suggestions that polymorphisms of the CD36 gene modulate lipid
metabolism and cardiovascular risk in Caucasians (Nozaki et al. 1999; Kintaka et al.
2002; Ma et al. 2004). Some authors have concluded that CD36 mRNA expression
in circulating monocytes might be a marker of coronary artery disease (Teupser
et al. 2008). There is no clear indication whether mutations of the CD36 receptor
gene protect against or increase the risk of hypercholesterolemia, atherosclerosis,
and its complications such as vascular dysfunction, progression of arterial
hypertension, and ischemic heart disease (Stein et al. 2002).
The objective of this study was to investigate whether there is an association
between the sequence changes in the CD36 gene region encoding the oxLDL- and
fatty acid-binding domain and the presence of some known risk factors in Caucasian
patients with coronary artery disease (CAD) at a young age.
Materials and Methods
The study group comprised 90 patients with CAD. The 66 men were no older than
50 years and the 24 women no older than 55 years. The patients were all Polish
residents treated in the Department of Cardiology of the County Hospital in
Szczecin (northwestern Poland) in 2007–2010. Clinically stable patients with
optimal pharmacological treatment and no acute coronary syndrome or revascular-
ization procedures within the previous month were included in the study. Patients
with hemodynamically signiﬁcant congenital or acquired valvular heart disease,
symptomatic heart failure (NYHA class[1), renal failure (creatinine[3 mg/dl),
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123type 1 diabetes mellitus, thyroid dysfunction (current hypo- or hyperthyroidism), or
malignancy were excluded from the study. The criteria for CAD diagnosis included
angiographically documented presence of at least one coronary lesion (C 40%
diameter stenosis of the left main coronary artery or C 50% stenosis of one of the
three major epicardial arteries, or C 70% stenosis of a branch) or a history of
revascularization procedure, or evidence of past myocardial infarction. The fasting
blood sample was taken for DNA extraction, complete blood count, and
measurements of serum glucose, high-sensitivity C-reactive protein (hsCRP), lipid
proﬁle (total, high- and low-density lipoprotein cholesterol, and triacylglycerols),
ApoA1, ApoB, and Lp(a). Each patient’s weight, height, waist and hip circumfer-
ence, and systolic and diastolic blood pressure were measured, and the body mass
index, waist-to-hip ratio, and mean arterial pressure were calculated. Genomic DNA
was isolated as previously described (Lahiri and Schnabel 1993). Amplicons of
exons 4 and 5 including fragments of introns were studied using the denaturing
high-performance liquid chromatography (DHPLC) technique as previously
described (Rac ´ et al. 2010). PCR products with alterations detected by DHPLC
were bidirectionally sequenced using the Applied Biosystems Dye-terminator Cycle
Sequencing Ready Reaction kit, according to the manufacturer’s protocol. Semi-
automated sequence analysis was performed using a 373A DNA fragment analyzer
(Applied Biosystems, Foster City, CA).
The study complies with the principles outlined in the Declaration of Helsinki
and was approved by our institutional ethics committee. Informed consent was
obtained from each patient.
Differences between subgroups of patients classiﬁed according to the CD36
genotype were tested with the Mann–Whitney U test for quantitative variables and
Fisher’s exact test for qualitative variables. Odds ratio (OR) and its 95% conﬁdence
interval (95% CI) were calculated for statistically signiﬁcant associations between
genotype and qualitative variables. The consistency of genotype distribution with
Hardy–Weinberg equilibrium was assessed using the exact test.
Results
Changes detected by DHPLC included two single nucleotide substitutions in
introns, IVS3-6 T/C (rs3173798) and IVS4-10 G/A (rs3211892) (Table 1). No
sequence alterations were found in exons. Genotype distributions were consistent
with Hardy–Weinberg equilibrium for both sequence changes (P = 1).
Table 1 CD36 sequence alterations in 90 patients with coronary artery disease
CD36 region DNA sequence alteration
a Genotype frequency Minor allele
frequency (%)
Intron 3 IVS3-6 T/C (rs3173798) 81.1% TT, 18.9% TC 9.4
Intron 4 IVS4-10 G/A (rs3211892) 92.2% GG, 7.8% GA 3.9
a Detected initially by DHPLC and then conﬁrmed by direct sequencing
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123The clinical data and morphometric parameters of patients showed differences
between the CD36 genotypes (Table 2). Body mass index was slightly higher
(P = 0.08) and obesity (BMI C 30 kg/m
2) was slightly more frequent in the IVS3-6
TC heterozygotes than in the TT patients (OR = 2.93, 95% CI 0.98–8.76,
P = 0.07). TC heterozygotes were also characterized by a higher prevalence of
diabetes (OR = 6.09, 95% CI 1.66–22.32, P = 0.009), and they received calcium
channel blockers more frequently than TT homozygotes (OR = 4.98, 95% CI
1.51–16.39, P = 0.01). In the subgroup of patients with past myocardial infarction,
the TC genotype was associated with a slightly younger age at this event
(P = 0.057). On the contrary, IVS4-10 GA heterozygotes had a signiﬁcantly older
age at the ﬁrst myocardial infarction than wild-type GG homozygotes (P = 0.003).
The blood count and biochemical data also revealed differences between the
CD36 genotypes (Table 3). The mean corpuscular hemoglobin concentration was
slightly higher (P = 0.06) and basophil percentage of the white blood cells was
signiﬁcantly lower (P = 0.03) in the IVS3-6 TC heterozygotes than in the TT
patients. The IVS3-6 TC genotype was also associated with signiﬁcantly higher
hsCRP (P = 0.02) but with lower Lp(a) (P = 0.01). The IVS4-10 GA genotype was
associated only with signiﬁcantly higher white blood cell count (P = 0.03).
Discussion
In intron fragments adjacent to the tested exons, we found IVS3-6 T/C (rs3173798)
and IVS4-10 G/A (rs3211892) polymorphisms. The IVS3-6C allele frequency
(9.4%) was similar to that described earlier in Caucasian populations (6.2–11.2%),
according to the NCBI dbSNP database. The IVS4-10A allele frequency (3.9%) was
slightly higher than that described in Caucasians (1.6–2.6%) according to the
dbSNP.
The IVS3-6 T/C polymorphism is located at a conserved splice site (Fry et al.
2009). The functional effects of both polymorphisms have not been elucidated so
far.
The effect of both single nucleotide polymorphisms (rs3173798 and rs3211892)
of CD36 on initial clinical presentation of coronary artery disease as myocardial
infarction or stable angina was analyzed in the American population, where more
than half of the subjects studied were Caucasians (Knowles et al. 2007). It was
shown that neither of the two alterations is signiﬁcantly associated with myocardial
infarction. Patients with myocardial infarction as an initial presentation of CAD,
however, had a signiﬁcantly higher frequency of the minor allele of another
polymorphism in intron 14 (rs3211956), which is not known to have functional
effects. In our study, we observed a trend (P = 0.057) or signiﬁcant association
(P = 0.003) between the IVS3-6 TC and IVS4-10 GA genotypes, respectively, and
age at myocardial infarction, but the direction of the association was reversed: the
age at the ﬁrst myocardial infarction was younger for TC but older for GA
heterozygotes.
In our study, the IVS3-6 TC heterozygous genotype was associated with three
cardiovascular risk factors: elevated hsCRP, higher prevalence of obesity, and
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123Table 2 Clinical and morphometric characteristics of 90 patients stratiﬁed by CD36 genotypes
Characteristic CD36 genotype
IVS3-6 T/C (rs3173798) IVS4-10 G/A (rs3211892)
TT TC P-value GG GA P-value
Number of patients 73 17 83 7
Gender (% male) 70% 88% 0.14 79% 86% 0.67
Blood pressure (mmHg)
Systolic 130.0 ± 14.0 120.0 ± 18.0 0.92 128.0 ± 15.0 130.0 ± 16.0 0.59
Diastolic 80.0 ± 9.0 80.0 ± 11.0 0.83 80.0 ± 9.0 80.0 ± 10.0 0.81
Mean arterial
pressure
93.3 ± 9.4 96.7 ± 10.9 1.00 93.3 ± 9.5 96.7 ± 11.2 0.61
Heart rate (1/min) 70.0 ± 7.0 72.0 ± 6.0 0.22 70.0 ± 6.4 64.0 ± 13.0 0.20
Obesity
Weight (kg) 84.0 ± 16.8 88.0 ± 18.6 0.21 84.0 ± 17.5 76.0 ± 13.3 0.45
Body mass
index (kg/m
2)
27.5 ± 3.7 29.7 ± 4.9 0.08 27.8 ± 4.0 27.4 ± 3.9 0.37
C25 kg/m
2 73% 82% 0.55 76% 71% 1.00
C30 kg/m
2 23% 47% 0.07 28% 29% 1.00
Waist (cm) 98.0 ± 4.2 103.0 ± 14.0 0.35 100.0 ± 12.4 93.0 ± 9.9 0.31
Hip (cm) 103.0 ± 7.9 104.0 ± 11.2 0.67 104.0 ± 8.9 101.0 ± 4.9 0.36
Waist-to-hip ratio 0.96 ± 0.10 0.98 ± 0.11 0.39 0.96 ± 0.10 0.94 ± 0.07 0.45
History of
hypertension
59% 71% 0.42 61% 57% 1.00
Age at diagnosis
of hypertension
(years)
43.5 ± 8.5 42.1 ± 9.7 0.99 42.9 ± 8.9 43.5 ± 5.3 0.82
Diabetes, type 2 8% 35% 0.009 13% 14% 1.00
Oral hypogly
cemic drugs
(% of patients
with diabetes)
83% 67% 1.00 82% 0% 0.25
Insulin (% of
patients
with diabetes)
17% 0% 1.00 0% 100% 0.08
Past myocardial
infarction
60% 65% 0.79 60% 71% 0.70
Age at ﬁrst
myocardial
infarction (years)
45.7 ± 5.8 42.2 ± 5.1 0.057 44.2 ± 5.6 51.0 ± 4.1 0.003
Current smoking 8% 24% 0.10 11% 14% 0.57
Past smoking 81% 100% 0.34 90% 100% 1.00
Treatment
Past percutaneous
transluminal
coronary
angioplasty
78% 65% 0.35 64% 100% 0.18
Past coronary
artery bypass
grafting
42% 35% 0.79 36% 0% 0.09
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123diabetes. No data to suggest an association between the CD36 variants and
anthropometric parameters or hsCRP levels in the Caucasian population have been
published so far. Lepre ˆtre et al. (2004) demonstrated a lack of association between
the IVS4-10 G/A alteration and adiponectin levels in the Caucasian population. On
the other hand, it was demonstrated that all of the CD36 sequence alterations studied
by Love-Gregory et al. (2008) (rs3211850 located in intron 3; rs3173804 located in
intron 9; nonsense mutation rs3211938 located in exon 10; rs7755, rs13246513, and
rs13230419 located in the 30 UTR) in African Americans with hypertension were
associated with such anthropometric parameters as body mass index above 30 kg/
m
2 and waist circumference above 100 cm.
It has been demonstrated that rs1527479 CD36 promoter polymorphism is
associated with insulin resistance and type 2 diabetes in Caucasians (Corpeleijn et al.
2006). On the other hand, no association has been described so far between CD36
variants investigated in our study and the prevalence of type 2 diabetes. Type 2
diabeteswasdiagnosedmorefrequentlyinIVS3-6TCheterozygotesthaninwild-type
homozygotes. The fasting serum glucose concentration, however, did not differ
betweenthegroups,whichmaybebecausemostoftheTCheterozygoteswithdiabetes
took oral hypoglycemic agents or insulin. IVS4-10 GA heterozygotes did not differ
fromwild-typehomozygotesintheprevalenceoftype2diabetes.Asimilarresultwas
published in the study by Lepre ˆtre et al. (2004), where no association was found
between the IVS4-10 G/A alteration and type 2 diabetes in the Caucasian population.
Some authors have reported that some promoter (rs10499859, rs109654) and
intron (rs1358337) CD36 polymorphisms in African Americans may contribute to
an increase in HDL plasma concentrations (Love-Gregory et al. 2008). Other
authors (Goyenechea et al. 2008) have shown an association between the CD36
promoter rs2151916 polymorphism and LDL levels in the St. Thomas UK Adult
Twin Registry cohort: LDL cholesterol concentrations were signiﬁcantly lower in
minor allele homozygotes. IVS3-6 T/C and IVS4-10 G/A polymorphisms were not
analyzed in that study. Ma et al. (2004) reported a correlation of two polymorphisms
Table 2 continued
Characteristic CD36 genotype
IVS3-6 T/C (rs3173798) IVS4-10 G/A (rs3211892)
TT TC P-value GG GA P-value
Angiotensin 1
converting
enzyme
inhibitors
81% 76% 0.47 77% 86% 1.00
Angiotensin 2
receptor blockers
17% 24% 0.47 14% 29% 0.34
Beta-blockers 82% 88% 1.00 82% 100% 0.59
Diuretics 24% 41% 0.37 30% 0% 0.17
Calcium channel
blockers
12% 41% 0.01 18% 14% 1.00
Statins 99% 88% 0.10 99% 86% 0.22
Unless otherwise noted, values are the mean ± SD or the percentage of patients with the indicated genotype
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123(rs1984112, rs1761667) at alternative transcription start sites (exons 1A and 1B),
one polymorphism (rs1527483) in intron 11, and two polymorphisms (rs3840546,
rs1049673) in an alternative 30 UTR region (exons 14 and 15) with plasma free fatty
acid metabolism in Caucasians. The authors investigated patients with type 2
diabetes stratiﬁed into CAD-positive cases and CAD-negative controls. Their results
suggest that all of those alterations in CD36 may be associated with an increased
risk of CAD, but the IVS3-6 T/C and IVS4-10 G/A polymorphisms were not
investigated in their study. In our study, we did not observe any statistically
Table 3 Blood count and biochemical data for 90 patients stratiﬁed by CD36 genotypes
Parameter CD36 genotype
IVS3-6 T/C (rs3173798) IVS4-10 G/A (rs3211892)
TT TC P-value GG GA P-value
Number of patients 73 17 83 7
Blood count
White blood cells
(G/L)
6.7 ± 2.2 7.5 ± 1.5 0.17 6.8 ± 2.1 8.6 ± 2.1 0.03
Red blood cells (T/L) 4.9 ± 0.4 4.9 ± 0.4 0.53 5.0 ± 0.4 4.8 ± 0.5 0.29
Hemoglobin (g/dL) 15.0 ± 1.2 15.0 ± 1.2 0.90 15.0 ± 1.2 14.9 ± 1.3 0.89
Hematocrit (%) 44.3 ± 3.3 43.6 ± 3.1 0.59 44.2 ± 3.3 43.9 ± 3.3 0.96
Mean corpuscular
(MC) volume (fL)
90.2 ± 4.5 88.6 ± 4.1 0.50 89.8 ± 4.4 92.4 ± 4.4 0.17
MC hemoglobin
(pg/erythrocyte)
30.0 ± 1.7 34.1 ± 1.8 0.60 30.1 ± 1.7 30.7 ± 2.3 0.43
MC hemoglobin
concentration (g/dL)
33.5 ± 0.8 34.1 ± 0.9 0.06 33.7 ± 0.8 33.5 ± 1.0 0.99
Platelets (G/L) 215.5 ± 43.8 228.0 ± 47.1 0.10 220.0 ± 44.3 223.0 ± 57.0 0.77
Neutrophils (%
white blood cells)
55.0 ± 8.8 51.4 ± 9.8 0.34 54.5 ± 8.7 47.3 ± 12.0 0.62
Lymphocytes (%) 33.9 ± 8.7 37.1 ± 8.3 0.36 33.4 ± 7.8 38.4 ± 10.3 0.64
Monocytes (%) 9.1 ± 2.0 9.8 ± 1.9 0.60 9.1 ± 1.9 10.0 ± 2.3 0.46
Eosinophils (%) 2.1 ± 1.9 2.2 ± 1.9 0.66 2.2 ± 1.9 1.4 ± 1.0 0.30
Basophils (%) 0.37 ± 0.20 0.25 ± 0.15 0.03 0.34 ± 0.20 0.30 ± 0.20 0.39
High-sensitivity
C-reactive protein
(mg/L)
1.1 ± 1.8 1.9 ± 2.9 0.02 1.2 ± 2.1 1.3 ± 2.7 0.73
Glucose (mg/dL) 100.5 ± 23.4 102.2 ± 18.8 0.64 100.3 ± 20.8 107.0 ± 38.3 0.55
Lipid proﬁle (mg/dL)
Total cholesterol 163.5 ± 37.8 159.0 ± 26.4 0.52 161.0 ± 36.9 167.0 ± 22.5 0.52
HDL cholesterol 47.5 ± 11.6 41.0 ± 12.9 0.17 47.0 ± 11.6 45.0 ± 15.6 0.87
LDL cholesterol 90.5 ± 33.3 88.0 ± 26.7 0.39 90.0 ± 33.3 96.0 ± 17.2 0.59
Triacylglycerols 126.5 ± 52.4 149.0 ± 69.8 0.43 128.0 ± 57.2 137.0 ± 45.1 0.99
Lp(a) (mg/dL) 23.1 ± 54.4 10.3 ± 29.0 0.01 20.7 ± 53.1 10.8 ± 19.6 0.22
ApoA1 (mg/dL) 148.0 ± 42.0 144.0 ± 29.0 0.42 148.5 ± 41.1 139.0 ± 22.0 0.64
ApoB (mg/dL) 74.5 ± 20.4 74.0 ± 16.2 0.41 73.0 ± 20.4 77.0 ± 6.4 0.47
Unless otherwise noted, values are the mean ± SD of patients with the indicated genotype
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123signiﬁcant differences in serum lipid concentrations between genotype groups. It is
worth noting that almost all of our study subjects, while being under constant
cardiologic monitoring, took statins, which could affect the results concerning
lipids. On the other hand, we observed that the IVS3-6 TC genotype was associated
with lower Lp(a), which is identiﬁed as a putative risk factor for atherosclerotic
diseases such as coronary heart disease and stroke. Such association could
potentially be beneﬁcial for carriers of the variant C allele.
It has been demonstrated (Chilongola et al. 2009) that a homozygous nonsense
mutation in exon 10 (rs3211938) is associated with high blood hemoglobin
concentrationinAfricans.Inourstudy,wedidnotobserveanystatisticallysigniﬁcant
differences in blood hemoglobin concentration between the genotype groups. We
found in turn that the mean corpuscular hemoglobin concentration in erythrocytes is
borderline higher and basophil percentage is signiﬁcantly lower in IVS3-6 TC
heterozygotes, and the white blood cell count is higher in IVS4-10 GA heterozygotes
than in wild-type homozygotes. No such associations have been reported so far.
In conclusion, the IVS3-6C allele of CD36 is associated with cardiovascular risk
factors such as high hsCRP, body mass index, and type 2 diabetes. On the other
hand, this variant is associated with low Lp(a), suggesting its protective effect in
terms of development of atherosclerosis. The IVS3-6C allele is associated with a
younger age at myocardial infarction and IVS4-10A with an older age. Further
research is necessary to assess their functional implications for the risk and clinical
course of coronary artery disease.
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